| 晚期十二指肠癌肝转移一线化疗方案的临床观察 |
| |
| 引用本文： | 潘 军,王 琳,杨宁蓉.晚期十二指肠癌肝转移一线化疗方案的临床观察[J].现代肿瘤医学,2018,0(16):2568-2572. |
| |
| 作者姓名： | 潘 军 王 琳 杨宁蓉 |
| |
| 作者单位： | 南京中医药大学附属八一医院全军肿瘤中心肿瘤内科，江苏 南京 210002 |
| |
| 基金项目： | 全军医学科技青年培育项目(编号:13QNP043) |
| |
| 摘 要： | 目的:探讨晚期十二指肠癌肝转移患者一线化疗方案的疗效和安全性。方法:回顾分析本院2008年6月至2016年1月收治的晚期十二指肠癌肝转移患者23例，6例未化疗，17例化疗，其中GEMOX方案8例、FOLFOX方案9例。采用Log-rank法进行生存分析。采用RECIST 1.1版与NCI-CTC 4.0版标准评价近期疗效和不良反应。结果:17例化疗患者均可评价疗效和不良反应，共完成化疗83个周期，中位化疗4个周期(2~12个周期)。GEMOX组获PR 1例、SD 5例、PD 2例，DCR为75.0%。FOLFOX组获SD 5例、PD 4例，DCR为55.6%。两组均无CR病例。23例肝转移患者的中位OS为9.8个月。17例化疗患者的中位OS为13.2个月，6例未化疗患者的中位OS为4.4个月，差异有统计学意义(P=0.032)。GEMOX组的中位OS为13.2个月，FOLFOX组的中位OS为10.3个月，差异无统计学意义(P=0.816)。GEMOX组的中位PFS为4.9个月，FOLFOX组的中位PFS为2.5个月，差异无统计学意义(P=0.468)。常见不良反应多为1-2级，主要为白细胞减少、中性粒细胞减少、贫血、乏力及恶心等。结论:肝转移影响晚期十二指肠癌患者的预后。化疗可延长晚期十二指肠癌肝转移患者的生存。GEMOX方案和FOLFOX方案均对晚期十二指肠癌肝转移一线治疗有效，且耐受性良好。GEMOX方案可能有更好的生存获益。
|
| 关 键 词： | 晚期十二指肠癌 肝转移 一线化疗 |
Clinical observation of first-line chemotherapy in advanced duodenal cancer with liver metastasis |
| |
| Pan Jun,Wang Lin,Yang Ningrong.Clinical observation of first-line chemotherapy in advanced duodenal cancer with liver metastasis[J].Journal of Modern Oncology,2018,0(16):2568-2572. |
| |
| Authors: | Pan Jun Wang Lin Yang Ningrong |
| |
| Affiliation: | Department of Medical Oncology,Cancer Center of PLA,81 Hospital Affiliated to Nanjing University of Chinese Medicine,Jiangsu Nanjing 210002,China. |
| |
| Abstract: | Objective:To explore the efficacy and safety of first-line chemotherapy in advanced duodenal cancer with liver metastasis.Methods:From June 2008 to January 2016,23 advanced duodenal cancer with liver metastasis patients were analyzed.Only 17 patients received chemotherapy,including 8 patients of GEMOX regimen,9 patients of FOLFOX regimen.Survival analysis was performed by using Log-rank method.The efficacy and safety were evaluated by RECIST 1.1 and NCI-CTC 4.0 criteria.Results:The total treatment cycle of chemotherapy was 83,and the median treatment cycle was 4(2~12 cycles).CR was not observed.For GEMOX regimen,1 case of PR and 5 cases of SD and 2 cases of PD were observed with disease control rate（DCR) of 75.0%.For FOLFOX regimen,5 cases of SD and 4 cases of PD were observed with DCR of 55.6%.The median OS of all patients was 9.8 months.The median OS of chemotherapy and non-chemotherapy were 13.2 months and 4.4 months（P=0.032).The median OS of GEMOX and FOLFOX regimen were 13.2 months and 10.3 months（P=0.816).The median PFS of GEMOX and FOLFOX regimen were 4.9 months and 2.5 months（P=0.468).The major treatment-related side effects including leucopenia,neutropenia,anemia,fatigue,nausea and etc,were mainly in grade 1-2.Conclusion:Liver metastasis may serve as strong factor with advanced duodenal cancer.Advanced duodenal cancer with liver metastasis may benefit from chemotherapy.GEMOX and FOLFOX regimen were effective and well-tolerated in first-line chemotherapy.GEMOX regimen had a longer OS and PFS in first-line chemotherapy. |
| |
| Keywords: | advanced duodenal cancer liver metastasis first-line chemotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
|
